NLNK stock: buy or sell?
June 26th, 2019
NewLink Genetics Corporation, a biopharmaceutical company, focuses on discovering, developing, and commercializing immunotherapeutic products for the treatment of cancer.
Should I buy NLNK stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Following a trading strategy helps to make decisions easier, quicker and with less hesitations. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
Currently, NewLink Genetics stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is NewLink Genetics stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we found 1 rating published for NLNK stock in the last 30 days.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-1-3||Bank of America||Neutral||Underperform|
NLNK stock analysis
Shares of NewLink Genetics collapsed a dreadful -3.85% and closed at $1.50.
NewLink Genetics shares collapsed -3.85% to $1.50 today. NLNK is soaring again after a 8.54% correction from its last top on Jun/13 at $1.64. For the last 21 days when NLNK stock price broke down the SMA100d line, it slid $-0.31 per share (-17.13%).
NewLink Genetics ended this week at $1.50 and fell a shocking -4.46%. Late May NLNK climbed an outstanding 16.93% in just one week. Early June NLNK collapsed a chilling -12.82% in just one week.
Since late May, when NLNK stock price broke down the 40-weeks moving avarage line, it slid $-0.39 per share (-20.63%). Trading stocks that are under the 40-weeks (that is, 200-days) moving average mark is not recommended by many experts, as it indicates that the stock has not enough institutional support.
NLNK stock price history
NLNK stock went public on November 11th, 2011 with a price of $7.001. Since then, NLNK stock declined a -78.60%, with a yearly average of -11.20%.
1: Adjusted price after possible price splits or reverse-splits.
NLNK stock historical price chart
NLNK stock reached 52-week highs at $5.24, and all-time highs 2015-04-09 with a price of 58.73.
NLNK stock price targetHow much a stock will be priced tomorrow or next week is quite unpredictable However, many stock price predictions are published every day by banks, financial institutions and independent analysts. You should not follow the analysts' NLNK stock price predictions in the hope that they will be met as they may be wrong and not met. For the last month we have not detected any price prediction for NewLink Genetics stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per ShareNewLink Genetics disappointed experts on February when it posted an Earnings per Share (EPS) of $-0.28 when the analysts' forecast was $-0.34.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, NewLink Genetics annual revenues plummed a chilling -56.55% to $12.47 M USD from $28.71 marked in 2017. When comparing 2018 vs 2017, similarly, profit margin (that is, the net income divided by revenues) plummed a -179.05% to -429.65%.
|2013||$1.09 M||-||$-31.18 M-2860.6%||-|
|2014||$173 M||15,734.13%||$103 M59.6%||-429.88%|
|2015||$69 M||-60.31%||$-40.38 M-58.9%||-139.26%|
|2016||$36 M||-47.78%||$-85.16 M-238.1%||110.88%|
|2017||$29 M||-19.73%||$-71.95 M-250.6%||-15.51%|
|2018||$12 M||-56.55%||$-53.60 M-429.7%||-25.51%|
Quarterly financial resultsNewLink Genetics posted $0.20 M in revenues for 2018-Q4, a 68.33% improvement compared to previous quarter. Reported quarter income marked $-10.57 million with a profit margin of -5,232.18%. Profit margin rocketed a 936.99% compared to previous quarter when profit margin was -6,169.17%. When comparing sales to same quarter last year, NewLink Genetics sales marked a frightening correction and plunged a -98.00%.
|2017-Q1||$3 M||-||$-20.91 M-757.6%||-|
|2017-Q2||$10 M||275.72%||$-16.73 M-161.3%||-19.99%|
|2017-Q3||$5 M||-47.14%||$-20.63 M-376.2%||23.29%|
|2017-Q4||$10 M||84.20%||$-13.69 M-135.5%||-33.65%|
|2018-Q1||$10 M||-1.96%||$-18.31 M-184.9%||33.79%|
|2018-Q2||$2 M||-77.25%||$-17.31 M-768.8%||-5.45%|
|2018-Q3||$0 M||-94.67%||$-7.40 M-6169.2%||-57.24%|
|2018-Q4||$0 M||68.33%||$-10.57 M-5232.2%||42.77%|
NewLink Genetics ownershipWhen you are planning to invest in shares of a stock, it's worth to overview its ownership structure.
NewLink Genetics shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 22.52% of all shares.
In case of NewLink Genetics stock, 34.73% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for NLNK stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to NewLink Genetics:
|Market cap||$55.9 M||$73.7 B||$377.3 B||$102.5 B||$286.8 M|
|Total shares||37.3 M||1,640.0 M||2,660.0 M||920.8 M||36.8 M|
|Float shares||26.1 M||1,630.0 M||2,650.0 M||802.0 M||15.8 M|
|- Institutional holdings (%)||34.7%||75.0%||69.2%||81.5%||72.6%|
|- Insider holdings (%)||22.5%||0.1%||0.1%||0.1%||12.8%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Wednesday, June 26th, 2019|
|Day range||$1.49 - $1.57|
|Average true range||$0.09|
|50d mov avg||$1.66|
|100d mov avg||$1.71|
|200d mov avg||$1.82|
NewLink Genetics performanceStocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. We compared NewLink Genetics against Bristol-Myers Squibb, , Eli Lilly and, Molecular Templates, Pfizer, SIGA Technologies, Sarepta Therapeutics and Sinovac Biotech in the following table:
|LLYEli Lilly and||-13.72%||-1.43%||33.33%|